Meningokokken-Impfung

Zusammenfassung

In Deutschland werden bereits Polysaccharid- und Konjugatimpfstoffe gegen Meningokokken der Serogruppe A, C, W135 und Y nach STIKO-Empfehlung eingesetzt. Seit An-fang 2013 ist nun auch ein neuer rekombinanter 4-Komponenten-MeningokokkenB-Impfstoff (4CMenB) zugelassen. Die Abdeckung der in Deutschland zirkulierenden Stämme durch den Impfstoff beträgt ungefähr 80 %. Immunogenität und Sicherheit sind für unterschiedlichste Impfschemata im Säuglingsalter und darüber hinaus untersucht, ebenso die Koadministrationen mit Standardimpfstoffen. Die STIKO hat im Dezember 2013 eine Stellungnahme zum Stand der Bewertung des neuen MeningokokkenB-Impfstoffes Bexsero herausgegeben.

Summary

In Germany polysaccharide and conjugate vaccines against meningococci A, C, W135 and Y are already used according to STIKO recommendations. Since early 2013 a new recombinant 4 component meningococcus B vaccine (4CMenB) has been approved. The coverage of the circulating strains of the vaccine is aprroximately 80 %. Immunogenicity and safety data for different vaccine schedules were generated in several studies, as well as for the co-administration with routine vaccines. The STIKO has released a comment to the current evalaution if the meningicoccal B vaccine Bexsero in december 2013.

Schlüsselwörter

Meningokokken - Impfung - Impfplan - Studien

Keywords

Meningococci - vaccine - vaccination-schedule - study

• Literatur

• 1 Pollard AJ, Nadel S, Ninis N. et al. Emergency management of meningococcal disease: eight years on. Arch Dis Child 2007; 92: 283-286.
• 2 European Union Invasive Bacterial Infections Surveillance Network. Invasive Neisseria meningitidis in Europe (2006) [Accessed 06.07.2012]. Available at www.hpa-bioinformatics.org.uk/euibis/neisseria.htm
• 3 WHO Strategic Advisory Group of Experts on Immunization (SAGE). Meningococcal vaccines: WHO position paper Weekly Epidemiological Record. 2011; 86: 521-540.
• 4 Epidemiologisches Bulletin, Nr. 32, 2008 www.rki.de
• 5 Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus I-V. J Exp Med 1969; 129: 1307-1395.
• 6 Granoff DM, Pollard AJ. Reconsideration of the use of Meningococcal Polysaccharide Vaccine. Pediatr Infect Dis J 2007; 26: 716-722.
• 7 Snape MD, Pollard AJ. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 2005; 5: 21-30.
• 8 Conterno LO, Silva Filho CR, Rüggeberg JU, Heath PT. Conjugate vaccines for preventing meningococcal C meningitis and septicaemia. Cochrane Database Syst Rev 2006; 19 3: CD 001834
• 9 Trotter CL, Andrews NJ, Kaczmarski EB. et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364: 365-367.
• 10 Jackson LA, Jacobson RM, Reisinger KS. et al. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J 2009; 28: 86-91.
• 11 Reisinger KS, Black S, Stoddard JJ. Optimizing Protection Against Meningococcal Disease. Clin Pediatr (Phila) 2010; 49: 586-597.
• 12 Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther 2001; 11: 969-985.
• 13 Daten des Nationalen Referenzzentrums für Meningokokken für das Jahr 2011 www.meningococcus.uni-wuerzburg.de/startseite/berichte/daten_2011/
• 14 Donnelly J, Medini D, Boccadifuoco G. et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 2011; 107: 19490-19495.
• 15 Vogel U, Taha MK, Vazquez JA. et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 2013; 13: 416-425.
• 16 Gossger N, Snape MD, Yu LM. et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012; 307: 573-582.
• 17 Vesikari T, Esposito S, Prymula R. et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013; 381: 825-835.
• 18 Borrow R, Carlone GM, Rosenstein N. et al. Neisseria meningitidis group B correlates of protection and assay standardization - international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006; 24: 5093-5107.
• 19 Whitney CG, Pilishvili T, Farley MM. et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: amatched case-control study. Lancet 2006; 368: 1495-1502.
• 20 Dagan R, Givon-Lavi N, Greenberg D. et al. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis 2006; 201: 1570-1579.
• 21 Snape MD, Dawson T, Oster P. et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010; 29: e71-79.
• 22 Santolaya ME, O’Ryan ML, Valenzuela MT. et al. V72P10 Meningococcal B Adolescent Vaccine Study group. Lancet 2012; 379: 617-624.
• 23 Epidemisches Bulletin 30-33/2006 www.rki.de
• 24 Epidemiologisches Bulletin 7/2007 www.rki.de
• 25 Epidemiologisches Bulletin 32/2012 www.rki.de
• 26 Epidemiologisches Bulletin 49/2013 www.rki.de